ClinicalTrials.gg
RecruitingNCT04881240Updated Aug 31, 2026

Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

A Phase 1 interventional study of CD19-CAR(Mem) T-cells and Cyclophosphamide in Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory and Pediatric ALL, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by St. Jude Children's Research Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
Up to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital — 15 open to participants now, 25 under way, 1 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · St. Jude Children's Research Hospital.

Planned enrollment
18th of 57
60 · median 42
Started
2024
with 3 others
Phase 1
12 of 70
4 open now
Primary completion
2027-07
later than 12 of 24 live
Registered
54th of 70
by date

Among the 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital, this one is the 18th largest by planned enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2024, is one of 12 in phase 1, reaches primary completion later than 12 of the 24 other live ones, and was the 54th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

15 of the 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: Up to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital, or all of them as a file.
02

Study summary

This is a Phase I clinical study evaluating the safety and maximum tolerated dose of a novel CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells expressing a CD19-specific CAR 41BBz (CD19-CAR.CD45RA- negative T-cells) for the treatment of patients ≤ 21 years old with relapsed and/ or refractory CD19-positive leukemia.

Primary Objective

To determine the maximum tolerated dose (MTD) and characterize the safety profile and dose-limiting toxicities (DLTs) of treatment with allogeneic CD19-CAR.CD45RA-negative T-cells in pediatric, adolescent and young adult patients ≤ 21 years of age, with relapsed and/or refractory CD19-positive leukemia.

Secondary Objectives

  • To evaluate the anti-leukemic activity of allogeneic CD19-CAR.CD45RA-negative T-cells.
  • To determine rates and severity of graft-versus-host-disease (GVHD) after treatment with allogeneic CD19-CAR.CD45RA-negative T-cells.

Exploratory Objectives

  • To study the expansion, persistence and phenotype of allogeneic CD19-CAR.CD45RA-negative T-cells.
  • To characterize the cytokine profile in the peripheral blood and CSF after treatment with allogeneic CD19-CAR.CD45RA-negative T-cells.
  • To assess whether allogeneic CD19-CAR.CD45RA-negative T-cells acquire functional versus exhaustion-associated epigenetic programs.
  • To determine immune reconstitution post treatment, and the clonal structure and endogenous repertoire of allogeneic CD19-CAR.CD45RA-negative T-cells and relate inferred specificity to CAR response profiles.
  • To characterize incidence and mechanisms of relapse post-therapy with allogeneic CD19-CAR.CD45RA-negative T-cells.
Read the detailed description

This is a Phase I dose escalation study using a 3+3 study design. Two groups of patients will be evaluated in this study: group A - patients have received a prior stem cell transplant from their CAR T-cell donor; group B - patients have not received a prior stem cell transplant from their CAR T-cell donor. There will be up to 30 participants per group and a donor/ family member for each patient.

.

03

Conditions studied

  • Acute Lymphoblastic Leukemia, in Relapse
  • Acute Lymphoblastic Leukemia, Refractory
  • Pediatric ALL
04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion Criteria Eligibility Criteria for Donors: Apheresis and Manufacturing

  • Age ≥ 18 years old
  • At least single haplotype matched (≥ 3/6) family member
  • negative
  • For females of child bearing age: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment AND Not lactating with intent to breastfeed
  • Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance. *For Cohort A only, an ineligible donor may be used under urgent medical need if the reason for ineligibility was previously present at time of transplant determination.

For Cohort A only, identified recipient with CD19-positive leukemia

For Cohort B only, iIdentified recipient with relapsed and/or refractory CD19-positive leukemia who is not suitable to receive autologous CD19-CAR T-cell therapy as defined by the following:

  • Relapsed and/or refractory disease despite prior treatment with autologous CD19- CAR T-cell therapy
  • History of prior autologous leukapheresis failure
  • History of prior autologous CAR T-cell manufacturing failure
  • Unable to undergo autologous leukapheresis in the opinion of the study PI(s): examples may include - patient small size/low weight, inadequate T-cell counts, rapidly progressive leukemia, clinical status not amenable to apheresis

Eligibility Criteria for Patients: Pre-Treatment Evaluation*

Inclusion criteria

Inclusion

  • MEMCAR19 recipient candidate ≤\<21 years old with rRelapsed and/or refractory CD19-positive leukemia.

*Due to potential scheduling challenges, all recipients may not be offered the Pre-Treatment Evaluation consent. This will not be counted as a deviation.

Eligibility Criteria for Patients:Treatment

  • Age ≤ 21 years old
  • Relapsed and/or refractory CD19-positive leukemia*:

    • Refractory disease (defined as any of the following):

      • Primary refractory disease despite at least 2 cycles of an intensive chemotherapy regimen designed to induce remission
      • Refractory disease despite salvage therapy
    • Relapsed disease (defined as any of the following):

      • 2nd or greater relapse
      • Any relapse after hematopoietic cell transplantation (HCT)
      • 1st relapse if patient requires an allogeneic HCT as part of standard of care relapse therapy, but is found to be ineligible and/or unsuitable for HCT

CD19-positivity confirmed within 2 months and after receipt of any CD19-directed therapy

  • Patient cohorts:

    • Cohort A: patient has previously received a HCT from the selected CAR T-cell donor
    • Cohort B - patient has NOT previously received a HCT from the selected CAR T-cell donor.
  • For Cohort B only, not suitable to receive autologous CD19-CAR T-cell therapy as defined above in Criteria: Eligibility Criteria for Donors: Apheresis and Manufacturing
  • Detectable medullary CD19-positive leukemia
  • Estimated of ≥ 8 weeks
  • or Lansky performance score ≥ 50
  • No CNS-3 disease or any level of detectable leukemia in CNS with associated neurologic symptoms
  • If history of allogeneic HCT (regardless of donor type), prior to planned CAR T-cell infusion, must meet the following criteria:

    • ≥ 3 months from HCT
    • have recovered from prior HCT therapy
    • have no evidence of active within prior 2 months
    • have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned CAR T-cell infusion
  • Adequate cardiac function: ≥ 40% or shortening fraction ≥ 25% (function may be supported by pharmacologic therapy)
  • without evidence of arrhythmia
  • Adequate renal function: or radioisotope 50 ml/min/1.73m2 (GFR 40 ml/min/1.73m2 if \< 2 years of age)
  • Adequate pulmonary function: forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing
  • Total ≤ 3 times the for age, except in subjects with Gilbert's syndrome
  • (ALT) or aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age
  • No history of HIV infection
  • No evidence of severe, uncontrolled bacterial, viral or fungal infection
  • Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy
  • For females of child bearing age:

    • Not pregnant with negative serum or urine pregnancy test ≤ 7 days prior to enrollment AND Not lactating with intent to breastfeed
  • If sexually active, agreement to use until 6 months after CAR T-cell infusion
  • No history of reactions to murine protein-containing products
  • Not receiving systemic therapy exceeding the equivalent of 0.5 mg/kg/day of methylprednisolone ≤ 7 days prior to CAR T-cell infusion
  • Not receiving systemic therapy ≤ 14 days prior to CAR T-cell infusion, which will interfere with the activity of the CAR T-cell product in vivo (in the opinion of the study PI(s))
  • Not receiving intrathecal chemotherapy ≤ 7 days prior to CAR T-cell infusion

Exclusion criteria

Exclusion Criteria:

NA

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group A

    Participants in group A have received a prior stem cell transplant from their CAR T-cell donor.

    Biological: CD19-CAR(Mem) T-cells · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Mesna · Device: CliniMACS · Procedure: Leukapheresis

  • Experimental
    Group B

    Participants in group B have not received a prior stem cell transplant from their CAR T-cell donor.

    Biological: CD19-CAR(Mem) T-cells · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Mesna · Device: CliniMACS · Procedure: Leukapheresis

Interventions

  • BiologicalCD19-CAR(Mem) T-cells

    Allogeneic CD19-CAR.CD45RA-negative T-cells Intravenous infusion

  • Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.

    Also known as: Cytoxan

  • Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.

    Also known as: Fludara

  • DrugMesna

    Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide.

    Also known as: Mesnex

  • DeviceCliniMACS

    A CliniMACS device is used to select donor T-cells for manufacturing of the memory CAR T-cell product.

  • ProcedureLeukapheresis

    Leukapheresis is performed to collect the T cells that are needed to generate the CD19-CAR.CD45RA-negative T-cells product for the clinic study.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose of allogeneic, CD19-CAR.CD45RA-negative cells

    This phase I study includes dose escalation/de-escalation based on dose limiting toxicity (DLT) assessment to determine the maximum tolerated dose (MTD) of allogeneic, CD19-CAR.CD45RA-negative cells.

    Time frame: 4 weeks after CAR T-cell infusion

07

Study locations

1 of 1 sites recruiting
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
    Recruiting
    • Aimee C. Talleur, MD · Contactreferralinfo@stjude.org · 866-278-5833
    • Aimee C. Talleur, MD · Principal investigator
    • Stephen Gottschalk, MD · Principal investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Jul 2027, 40 months after the start.

Of 158 non-industry phase 1 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 92. This study's planned 40 months is below that.

Counting every sponsor, half of 208 studies reached it within 55 months; a quarter within 34 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2021
First posted
May 11, 2021
StartActual
Feb 14, 2024
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 1, 2028
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04881240
Responsible party
Sponsor
First posted
May 11, 2021
Start date
Feb 14, 2024
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
Aug 31, 2026

Study contacts

Aimee C. Talleur, MD
Contact
referralinfo@stjude.org
866-278-5833
Aimee C. Talleur, MD
principal investigator · St. Jude Children's Research Hospital
Stephen Gottschalk, MD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion